Travel Vaccines Market to grow by USD 3.97 billion between 2024-2028
According to a research report “ Travel Vaccines Market” by Disease Type (Influenza, Diptheria, Hepatitis, Typhoid and others) End-user (Adult vaccines, Pediatric vaccines) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 3.97 billion at a CAGR of almost 8.64% during the forecast period. The global increase in travel by air, sea, and land, as well as immigration activities, has led to a surge in the spread of pathogens and disease-causing vectors worldwide. This trend has significant implications for the travel vaccines market, particularly in relation to emerging diseases such as the H5N1 avian flu virus, which originated in poultry and subsequently affected humans. Furthermore, the transmission of diseases like tuberculosis from animals and plants to people, particularly in developing countries and among migrant groups, underscores the importance of effective vaccination programs to mitigate health risks for travelers..
Browse market data tables, figures, and in-depth TOC on “Travel Vaccines Market” by Disease Type (Influenza, Diptheria, Hepatitis, Typhoid and others) End-user (Adult vaccines, Pediatric vaccines) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.
View detailed Table of Content- Click here
By Disease Type, the Influenza segment is projected to dominate the market size in 2024.
In the realm of healthcare, adult vaccines represent a significant market segment, catering to the immunization needs of the 18-and-above demographic. These business-critical solutions safeguard against infectious diseases, which can pose serious health risks and consequences for adults. Key offerings within this market include vaccines for tetanus, diphtheria, pertussis (Tdap), influenza, pneumococcal disease, hepatitis A and B, and shingles. The travel sector presents a lucrative opportunity for this market, as adults venturing to regions with high disease incidence require these vaccines to mitigate the risk of contracting preventable illnesses while abroad.
By End-user, Adult vaccines segment is expected to hold the largest market size for the year 2024.
The influenza travel vaccines market is projected to experience substantial expansion during the forecast period, driven by the increasing incidence of influenza and subsequent hospitalizations worldwide. For instance, in the US alone, influenza virus infections led to approximately 8-13 million illnesses, 3.7-6.1 million doctor visits, 82,000-170,000 hospitalizations, and 5,000-14,000 fatalities between October 2021 and June 2022, according to the CDC. Key market players, including GlaxoSmithKline, Sanofi, and CSL, significantly contribute to this market as established vendors in the global vaccines sector.
North America is forecasted to hold the largest market size by region in 2024.
The North American region is expected to lead the global travel vaccines market due to the presence of organizations like the Pan American Health Organization (PAHO), which establish immunization guidelines. Major vaccines sold in this region include BOOSTRIX, INFANRIX, Pediarix, BEXSERO, MENVEO, and influenza vaccines. The surge in prevalence of both infectious and non-infectious diseases, particularly in developed countries such as the US, where influenza cases peak during November and persist until February, underscores the market's significance.
The Travel Vaccines Market t growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Travel vaccines play a crucial role in ensuring the health and safety of travellers against various disease hazards, particularly those associated with overseas travel. The travel vaccine market encompasses a range of vaccines designed to protect against travel-related diseases caused by pathogenic organisms, including attenuated organisms and microbes. These vaccines employ advanced technologies such as mRNA vaccines and recombinant DNA technology to provide immunity against infectious diseases and specialized strains. The prevalence of disease and the likelihood of exposure to pathogens vary significantly across different regions and countries. As such, the travel vaccine market caters to a diverse range of vaccine-preventable diseases, including yellow fever, hepatitis A and B, typhoid, cholera, and rabies. The market's growth is driven by the increasing number of international travellers, the gains of the biotechnology industry, and various initiatives aimed at enhancing travel safety. In conclusion, the travel vaccines market represents a vital component of the healthcare industry, providing essential protection against a range of travel-related diseases and contributing to the overall safety and wellbeing of travellers.
Market Research Overview
The Travel Vaccines Market encompasses a range of vaccine formulations designed to protect travellers from various disease types, including Cholera, Yellow fever, Hepatitis B virus, Dengue fever, and others. Novel vaccine technologies, such as mRNA and recombinant DNA, play a significant role in the development of these vaccines. DUKORAL and HEPLISAV B are examples of vaccines used for the prevention of Cholera and Hepatitis B, respectively. Travel clinics offer consultation fees and administration charges for travel vaccines, making it essential for first-time travellers to plan ahead. The substantial cost of these vaccines is a gain for the industry, which continues to invest in the research and development of new vaccines for travel-related diseases. Vaccines against pathogenic organisms like mumps, measles, typhoid, rabies, and others are crucial for ensuring travel safety and preventing illness. The use of attenuated organisms and microbes in vaccine formulations has led to the creation of specialized vaccines for infectious diseases. The Travel Vaccine Market is driven by the prevalence of diseases and the likelihood of exposure during overseas travel. Initiatives to increase immunization against vaccine-preventable diseases and the growing trend of medical tourism and vacations contribute to the market's growth. Safety, dosages, side effects, and proof of vaccination are essential considerations for travellers when planning their immunization schedule.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
